Grants per year
Personal profile
Research Interests
I have an interest in the development of clinical trials, as well as studying novel biomarkers that may be used as prognostic and predictive tools in the management of melanoma and other advanced skin cancers, as well as cancer of unknown primary.
Training Experience
| 2011 | Residency, Case Western Reserve University Hospital |
| 2014 | Fellowship, New York University Medical Center |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MD, Medicine, Michigan State University
… → 2008
MS, Michigan State University
… → 2003
Research interests keywords
- Cancer of Unknown Primary
- Clinical Research
- Drug Discovery
- Melanoma
- Skin Cancer
Fingerprint
Dive into the research topics where Sunandana Chandra is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #IMC-F106C-301: A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Chandra, S. (PD/PI)
Worldwide Clinical Trials, Inc., Immunocore Limited
9/30/24 → 9/30/27
Project: Research project
-
Prot #MT-8421-001: A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-8421 as Monotherapy and in Combination with Nivolumab in Patients wit
Chandra, S. (PD/PI)
6/21/24 → 6/21/27
Project: Research project
-
Prot #IMM1104-101: A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants with Previously Treated RAS-Mutated Advanced or Metastatic Solid Tumors
Chandra, S. (PD/PI)
Tempus Compass, LLC, Immuneering Corporation
3/15/24 → 3/15/27
Project: Research project
-
Prot #SGNBB228‐001: A Phase 1 Study of SGN‐BB228 in Advanced Melanoma and Other Solid Tumors
Chandra, S. (PD/PI)
7/11/23 → 7/11/26
Project: Research project
-
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6
Hughes, B. G. M., Guminski, A., Bowyer, S., Migden, M. R., Schmults, C. D., Khushalani, N. I., Chang, A. L. S., Grob, J. J., Lewis, K. D., Ansstas, G., Day, F., Ladwa, R., Stein, B. N., Muñoz Couselo, E., Meier, F., Hauschild, A., Schadendorf, D., Basset-Seguin, N., Modi, B. & Dalac-Rat, S. & 24 others, , Jan 2025, In: Journal of the American Academy of Dermatology. 92, 1, p. 68-77 10 p.Research output: Contribution to journal › Article › peer-review
-
Anatomic Subtype Differences in Extramammary Paget Disease: A Meta-Analysis
Kibbi, N., Owen, J. L., Worley, B., Wang, J. X., Harikumar, V., Aasi, S. Z., Chandra, S., Choi, J. N., Fujisawa, Y., Iavazzo, C., Kim, J. Y. S., Lawrence, N., Leitao, M. M., MacLean, A. B., Ross, J. S., Rossi, A. M., Servaes, S., Solomon, M. J. & Alam, M., Apr 17 2024, In: JAMA dermatology. 160, 4, p. 417-424 8 p.Research output: Contribution to journal › Article › peer-review
4 Scopus citations -
Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications
Akaike, T., Thakuria, M., Silk, A. W., Hippe, D. S., Park, S. Y., So, N. A., Maloney, N. J., Gunnell, L., Eschholz, A., Kim, E. Y., Sinha, S., Hall, E. T., Bhatia, S., Reddy, S., Rodriguez, A. A., Aleshin, A., Choi, J. S., Tsai, K. Y., Yom, S. S. & Yu, S. S. & 4 others, , Sep 10 2024, In: Journal of Clinical Oncology. 42, 26, p. 3151-3161 11 p.Research output: Contribution to journal › Article › peer-review
-
Melanoma: Cutaneous, Version 2.2024 Featured Updates to the NCCN Guidelines
Swetter, S. M., Johnson, D., Albertini, M. R., Barker, C. A., Bateni, S., Baumgartner, J., Bhatia, S., Bichakjian, C., Boland, G., Chandra, S., Chmielowski, B., DiMaio, D., Dronca, R., Fields, R. C., Fleming, M. D., Galan, A., Guild, S., Hyngstrom, J., Karakousis, G. & Kendra, K. & 18 others, , Jul 1 2024, In: JNCCN Journal of the National Comprehensive Cancer Network. 22, 5, p. 290-298 9 p.Research output: Contribution to journal › Article › peer-review
11 Scopus citations -
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers
Schenk, K. M., Deutsch, J. S., Chandra, S., Davar, D., Eroglu, Z., Khushalani, N. I., Luke, J. J., Ott, P. A., Sosman, J. A., Aggarwal, V., Schollenberger, M. D., Sharfman, W. H., Bibee, K. P., Scott, J. F., Loss, M. J., Wang, H., Qi, H., Sharon, E., Streicher, H. & Chen, H. X. & 6 others, , Mar 20 2024, In: Journal of Clinical Oncology. 42, 9, p. 1011-1020 10 p.Research output: Contribution to journal › Article › peer-review
13 Scopus citations